ObvioHealth Discusses Vaccine Clinical Trials Being Ripe for Virtualization

Orlando,United States - May 16, 2022 /PressCable/ —

ObvioHealth has released a page on its website exploring the potential for virtualization of vaccination clinical trials. Its article opens by noting how the success of mRNA vaccines has significantly increased expectations for the time required to finish a vaccine clinical trial. Pharmaceutical firms are reevaluating their practices in response. However, what are the appropriate and practical procedures for obtaining trial findings more quickly and economically?

There are three key factors that are essential to the successful completion of a vaccine clinical trial:

Safety: The immediate detection of adverse events

Study Power: Patient populations that are large and diverse enough to reduce the probability of false null hypotheses

Time: Data must be measured longitudinally to track changes in efficacy, safety, or patient health status

On all three counts, site-based studies have been criticized. They have smaller recruiting pools, higher participant annoyance, and less frequent check-ins.

According to one patient who participated in one of Moderna’s COVID-19 vaccine trials, the experience was “exhausting” and necessitated “seven hospital visits, 24 phone calls, dozens of diary entries, repeated batteries of questions about [his] private life, five blood draws, and numerous nasopharyngeal swabs.” While some of these restrictions are inescapable, others may be alleviated or simplified by the decentralization of specific processes in the trial process, which improves both the participant experience and the quality of the results.

Additionally, ObvioHealth discusses study power and the need to maintain appropriate size and variety of patient groups in vaccination clinical trials. Fortunately, adverse reactions to the majority of immunizations are uncommon. However, this requires huge patient populations in vaccination clinical trials to identify them and verify the correctness of research findings on a wide scale. It might be difficult to find and enroll a sufficient number of participants. Dropouts are also a problem, and are more prevalent in lengthier, more demanding studies.

As a consequence, having a large participant pool is critical to compensating for individuals that opt out. On-site recruitment may be very expensive and ineffective; in fact, many venues may fail to attract even one patient. Virtualization may assist researchers in overcoming these barriers by allowing them to contact and attract patients more cost effectively using targeted digital media. Geographic expansion enables more patients to be recruited more rapidly.

Researchers are now supplementing internet recruiting with collaborations in minute clinics or pharmacies to extend study participants even further. These collaborations offer alternatives for participants who are uncomfortable with digital enrolling or who prefer the convenience of in-person assistance. Additionally, participants might be recruited online for in-person visits. According to the CDC, more than 90% of the population in the United States lives within five miles of a community pharmacy, and people visit these facilities 12 times more often than they do their primary care practitioner. As a result, pharmacists play a critical role in delivering treatment to patients, particularly those who are economically and geographically neglected.

Along with recruiting and enrolling participants, these neighborhood clinics may serve as locations for follow-up blood draws or nasopharyngeal swabs. This enables participants to make follow-up visits to more convenient and familiar venues.

While virtual clinical trials offer a number of advantages across therapeutic areas, their unique nature makes them especially successful at assuring vaccine safety, expediting vaccine licensing, and permitting longer-term follow-up. Virtual technologies are assisting vaccination trials in demonstrating protection against viruses such as COVID-19 while also providing researchers with the rich data necessary to assess the long-term impact of vaccines on patient immunity and general health.

To find out more about ObvioHealth, see its website at the following URL: https://www.obviohealth.com/

Contact Info:
Name: James Hendrick
Email: Send Email
Organization: ObvioHealth USA, Inc.
Address: 3452 Lake Lynda Drive Suite 151, Orlando, Florida 32817, United States
Phone: +1-888-880-1664
Website: https://www.obviohealth.com/

Source: PressCable

Release ID: 89075190

If you detect any issues, problems, or errors in this press release content, kindly contact [email protected] to notify us. We will respond and rectify the situation in the next 8 hours.